Effect of atorvastatin on hepatic production of atherogenic lipoproteins in patients with insulin resistance syndrome/metabolic syndrome X

2000 ◽  
Vol 33 (3) ◽  
pp. 236
Author(s):  
L Pontrelli ◽  
R Cheung ◽  
W Parris ◽  
K Adeli
2007 ◽  
Vol 64 (1) ◽  
pp. 45-51 ◽  
Author(s):  
Aleksandra Nikolic ◽  
Dejan Nikolic ◽  
Violeta Stanimirovic

2002 ◽  
Vol 227 (3) ◽  
pp. 164-170 ◽  
Author(s):  
Rodney A. Velliquette ◽  
Richard J. Koletsky ◽  
Paul Ernsberger

Metabolic Syndrome X is a cluster of abnormalities including insulin resistance, hyperlipidemia, hypertension, and obesity. We sought to determine if excess plasma glucagon and free fatty acids (FFA) might contribute to the insulin resistance in the obese spontaneous hypertensive rat (SHROB), a unique animal model of leptin resistance and metabolic Syndrome X. SHROB were extremely hyperinsulinemic and mildly glucose intolerant compared with lean SHR. SHROB had elevated fasting plasma glucagon and FFA, and showed paradoxical responses to an oral glucose challenge, with increased glucagon at 30 and 60 min postchallenge (200% ± 45% and 91% ± 13%, respectively; n = 9). In lean SHR, glucagon was nearly unchanged by glucose loading (<30% increase, P > 0.05; n = 5). Plasma FFA were not affected by a glucose load in SHROB, whereas SHR showed a decrease of 40% ± 6% (n = 5–9). The I/G molar ratio changed in opposite directions in the two genotypes, with a decrease in SHROB at 30 and 60 min, in contrast to the appropriate increase at 30 and 60 min postchallenge in the lean SHR (P < 0.01; n = 5–9). Administration of 500 ng/kg exogenous glucagon to SHR raised glucagon 56% ± 5% to a level that was similar to fasting SHROB. This level of circulating glucagon was sufficient to elevate glucose and insulin during the 7 hr of observation (n = 9). Based on these results, we suggest that fasting hyperglucagonemia and impaired suppression of glucagon secretion and FFA in response to an oral glucose load may contribute to insulin resistance and glucose intolerance in the SHROB model of metabolic Syndrome X.


2015 ◽  
Vol 7 (1) ◽  
Author(s):  
Kae-Woei Liang ◽  
Wen-Jane Lee ◽  
Wen-Lieng Lee ◽  
Ying-Chieh Liao ◽  
Kuo-Yang Wang ◽  
...  

2021 ◽  
Author(s):  
Mimie Noratiqah Jumli ◽  
Muhammad Ilyas Nadeem

Insulin resistance syndrome or syndrome X is also known as metabolic syndrome (MetS). It is an emerging problem globally with the surge of increasing prevalence among urban population of developing countries. The etiology of pathophysiology of metabolic syndrome includes the inflammatory pathways of insulin resistance, deregulated appetite, diet-induced, inflammation-induced obesity, and cardiovascular diseases (CVD). Adipose tissue is an endocrine organ that secrets adipokines like adiponectin and resistin during physiological and pathological states. Moreover, the adipokines associated with diet-induced and inflammation-induced obesity have secondary deteriorating effects on cardiovascular system. Although, the adiponectin and resistin were potentially found in regulating food intake and appetite but their mediating effect on pathophysiology of CVD still needs future investigations. However, the prior studies reported the association of adiponectin and resistin levels with CVD complications related to food intake but still there is need to understand its multifactorial heterogeneity. Therefore, literature suggests figuring out potential target mechanistic and therapeutic approaches of adiponectin and resistin hormone towards food intake and appetite involvement in metabolic syndrome and CVD.


Sign in / Sign up

Export Citation Format

Share Document